KR930701196A - New treatment - Google Patents

New treatment

Info

Publication number
KR930701196A
KR930701196A KR1019920703296A KR920703296A KR930701196A KR 930701196 A KR930701196 A KR 930701196A KR 1019920703296 A KR1019920703296 A KR 1019920703296A KR 920703296 A KR920703296 A KR 920703296A KR 930701196 A KR930701196 A KR 930701196A
Authority
KR
South Korea
Prior art keywords
histamine
receptor antagonist
use according
acid
treatment
Prior art date
Application number
KR1019920703296A
Other languages
Korean (ko)
Inventor
프랜시스 데이빗 아드리안
Original Assignee
데이빗 로버츠
비이참 그루우프 피이엘시이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909013910A external-priority patent/GB9013910D0/en
Priority claimed from GB909018676A external-priority patent/GB9018676D0/en
Application filed by 데이빗 로버츠, 비이참 그루우프 피이엘시이 filed Critical 데이빗 로버츠
Publication of KR930701196A publication Critical patent/KR930701196A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/12—Magnesium silicate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

위 질병의 치료를 위한 히스타민 H2-수용기 길항제 및 제산제의 동시투여.Coadministration of histamine H 2 -receptor antagonists and antacids for the treatment of gastric diseases.

Description

신규한 치료New treatment

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (14)

테산제가 히스타민 H2-수용기 길항제의 pka의 수준과 실질적으로 같은 국부적 pH수준을 부여하는 평형 pH, 산 중화능력, 및 시간에 따른 pH분포를 제공하는 위 체류시간 값을 가지는 것을 특징으로 하는, 위 질병의 치료를 위한 약제의 제주를 위해 히스타민 H2-수용기 길항제 및 제산제로 구성되는 경구적으로 투여가능한 제약학적 조성물의 사용.The stomach acid is characterized by having an equilibrium pH, an acid neutralizing capacity, and a gas retention time value that provides a pH distribution over time that imparts a local pH level substantially equal to the pka level of the histamine H2-receptor antagonist. Use of an orally administrable pharmaceutical composition consisting of histamine H 2 -receptor antagonist and antacid for Jeju of a medicament for the treatment of a disease. 제1항에 있어서, 체벽 세포 수용기에서 히스타민 H2-수용기 길항제의 국부적 수준이 증가하고, 이로써 히스타민 H2-수용기 길항제의 산분비 감소 능력을 증가시키는 것을 특징으로 하는 사용.2. Use according to claim 1, characterized in that the local level of histamine H2-receptor antagonist is increased in body wall cell receptors, thereby increasing the acid secretion ability of the histamine H2-receptor antagonist. 제1또는 2항에 있어서, 궤양 환자에 있어서 위 질병의 치료를 위한 사용.Use according to claim 1 or 2 for the treatment of gastric diseases in ulcer patients. 제3항에 있어서, 동상의 히스타민 H2-수용기 길항제 치료요법에 응답하지 않는 환자의 치료를 위한 사용.Use according to claim 3 for the treatment of patients who do not respond to frostbite histamine H 2 -receptor antagonist therapy. 제3항에 있어서, 산 분비 과다 환자의 치료를 위한 사용.4. Use according to claim 3 for the treatment of patients with excess acid secretion. 제1또는 2항에 있어서, 급성 위 질병의 단일 투여 치료를 위한 사용.Use according to claim 1 or 2 for single dose treatment of acute gastric disease. 임의 앞선 항에 있어서, 히스타민 H2-수용기 길항제 시미티딘, 라니티딘, 또는 파모티딘인 사용.The use according to any preceding claim, which is the histamine H 2 -receptor antagonist cimitidine, ranitidine, or pamotidine. 제7항에 있어서, 히스타민 H2-수용기 길항제가 시메티딘인 사용.8. Use according to claim 7, wherein the histamine H 2 -receptor antagonist is cimetidine. 제8항에 있어서, 시메티딘의 투여량이 투여 형태당 25-400mg인 사용.Use according to claim 8, wherein the dose of cimetidine is 25-400 mg per dosage form. 제9항에 있어서, 시메티딘의 투여량이 투여 형태인 50-200mg인 사용.Use according to claim 9, wherein the dosage of cimetidine is 50-200 mg in dosage form. 임의 앞선 항에 있어서, 재산제가 수산화알루미늄, 수산화마그네슘, 수산화알루미늄-탄산마그넷슘 함께 건조된 겔, 탄산마그네슘, 산화 마그네슘, 삼규산 마그네슘, 중탄산나트륨, 탄산칼륨, 탄산비스무트, 마그네슘 알루미늄 규산염, 구연산, 주석산, 벤조산, 소르빈산 또는 인산의 알칼리 금속염, 또는 앞서 언급된 제산제중 임의의 조합물인 사용.The agent according to any of the preceding claims, wherein the retardant is aluminum hydroxide, magnesium hydroxide, aluminum hydroxide-magnesium carbonate dried gel, magnesium carbonate, magnesium oxide, magnesium trisilicate, sodium bicarbonate, potassium carbonate, bismuth carbonate, magnesium aluminum silicate, citric acid, Use is an alkali metal salt of tartaric acid, benzoic acid, sorbic acid or phosphoric acid, or a combination of any of the aforementioned antacids. 평행 pH, 산중화 능력 및 위 체류 시간 값이 히스타민 H2-수용기 길항제의 pka의 수준과 실질적으로 같은 pH수준을 부여하는 제산제 및 히스타민 H2-수용기 길항제로 구성되는 효과적 양의 제약학적 조성물을 환자에게 경구적으로 투여하는 것으로 구성되는 위 질병의 치료 방법.Patients with an effective amount of pharmaceutical composition consisting of an antacid and histamine H 2 -receptor antagonist whose parallel pH, acid neutralizing capacity and gastric retention time values confer a pH level substantially equal to the pka level of the histamine H 2 -receptor antagonist A method for the treatment of stomach diseases, which comprises orally administering to a patient. 평행 pH, 산 중화능력 및 위 체류신간 값이 히스타민 H2-수용기 길항제의 pka의 수준과 실질적으로 같은 pH수준을 붕여하는 제산제 및 히스타민 H2-수용기 길항제로 구성되는 위 질병의 치료에 사용하기 위한 제약학적 조성물.Parallel pH, acid neutralizing capacity and gastric residence NEW values are histamine H 2 - antacids that bungyeo the pH levels to a level substantially the pka of receptor antagonists and histamine H 2 - for use in the treatment of the above diseases consisting receptor antagonists Pharmaceutical compositions. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019920703296A 1990-06-22 1991-06-13 New treatment KR930701196A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB909013910A GB9013910D0 (en) 1990-06-22 1990-06-22 Novel treatment
GB9013910.6 1990-06-22
GB909018676A GB9018676D0 (en) 1990-08-24 1990-08-24 Novel treatment
GB9018676.8 1990-08-24
PCT/GB1991/000953 WO1992000102A1 (en) 1990-06-22 1991-06-13 Novel treatment

Publications (1)

Publication Number Publication Date
KR930701196A true KR930701196A (en) 1993-06-11

Family

ID=26297238

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920703296A KR930701196A (en) 1990-06-22 1991-06-13 New treatment

Country Status (7)

Country Link
EP (1) EP0533770A1 (en)
JP (1) JPH05507695A (en)
KR (1) KR930701196A (en)
AU (1) AU7981391A (en)
CA (1) CA2085873A1 (en)
IE (1) IE912133A1 (en)
WO (1) WO1992000102A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2052698A1 (en) * 1990-10-11 1992-04-12 Roger G. Berlin Treatment of peptic ulcer
CA2061520C (en) * 1991-03-27 2003-04-22 Lawrence J. Daher Delivery system for enhanced onset and increased potency
GB9127150D0 (en) * 1991-12-20 1992-02-19 Smithkline Beecham Plc Novel treatment
CA2110313C (en) * 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
WO1995001792A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-antihistamine combinations
US5622980A (en) * 1993-08-17 1997-04-22 Applied Analytical Industries, Inc. Oral compositions of H2-antagonists
ZA947553B (en) * 1993-09-30 1995-05-26 Glaxo Inc Ranitidine and calcium carbonate pharmaceutical combination product
JP3587869B2 (en) * 1993-12-16 2004-11-10 グラクソ・スミスクライン株式会社 Pharmaceutical composition
AU2912695A (en) * 1994-08-12 1996-03-07 Henry C Caldwell Oral compositions of h2-antagonists
US5989588A (en) * 1996-10-04 1999-11-23 Merck & Co., Inc. Methods and compositions for preventing and treating heartburn
ES2274550T3 (en) * 1996-10-04 2007-05-16 MERCK & CO., INC. PROCEDURES AND COMPOSITIONS TO PREVENT AND TREAT BURNING OF STOMACH.
EP1983827A4 (en) 2006-02-01 2013-07-10 Stuart L Weg Use of antifungal compositions to treat upper gastrointestinal conditions
MA46597A (en) 2015-05-29 2019-09-04 Johnson & Johnson Consumer Inc USE OF ORGANIC CITRUS EXTRACT WITH HIGH ANTIMICROBIAL CAPACITY AS A PRESERVATION SYSTEM IN LIQUIDS, EMULSIONS, SUSPENSIONS, CREAMS AND ANTI-ACIDS
EP3302420A1 (en) 2015-05-29 2018-04-11 Johnson & Johnson Consumer Inc. Use of an organic citrus extract with high antimicrobial capacity and xylitol as a preservative system in liquids, emulsions, suspensions, creams and antacids
WO2017091166A1 (en) 2015-11-26 2017-06-01 Pharmacti̇ve İlaç San. Ve Ti̇c. A.Ş. Stable pharmaceutical compositions and process for their preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3710462A1 (en) 1987-03-30 1988-10-13 Heumann Pharma Gmbh & Co PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF DISEASES OF THE gastrointestinal tract
ATE73328T1 (en) 1987-05-08 1992-03-15 Smith Kline French Lab PHARMACEUTICAL COMPOSITIONS.

Also Published As

Publication number Publication date
AU7981391A (en) 1992-01-23
CA2085873A1 (en) 1991-12-23
IE912133A1 (en) 1992-01-01
JPH05507695A (en) 1993-11-04
EP0533770A1 (en) 1993-03-31
WO1992000102A1 (en) 1992-01-09

Similar Documents

Publication Publication Date Title
KR930701196A (en) New treatment
JPH07502527A (en) Compositions containing low doses of histamine-H2-receptor antagonists
US5403830A (en) Compositions and methods of treating gastrointestinal disorders
WO1993021932A1 (en) Methods and pharmaceutical compositions for treating episodic heartburn
IE60726B1 (en) Pharmaceutical compositions
US3232833A (en) Heparin containing compositions
US3621094A (en) Concentrated aqueous liquid antacid compositions containing certain phosphate and gluconate salts
US4387093A (en) Arthritis treatment
Bejoy Hydrotalcite: the clay that cures
RU2126249C1 (en) Pharmaceutical composition for oral administration for treatment of patients with pathology of gastroenteric tract upper regions
Littman et al. Antacids and anticholinergic drugs
AU659422B2 (en) Composition containing antihistamine H2 receptor antagonists and bioadhesive material
JPH0539219A (en) Treatment by foamy h2 blocker of stamach trouble associated with heartburn, stomachache or excess acid
Paul et al. Effect of buffering agents on absorption of acetysalicylic acid
JP3587869B2 (en) Pharmaceutical composition
Vincent et al. The effect of large doses of calcium carbonate on serum and urinary calcium
HARDT et al. ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE PLUS MUCIN IN TREATMENT OF PEPTIC ULCER: Gastroscopic and Clinical Studies
Gangarosa et al. Drugs used in gastrointestinal disorders
JP2900056B2 (en) Pharmaceutical composition for prevention of gastric diseases caused by nonsteroidal anti-inflammatory drugs
Kupersmith Improved therapy for peptic ulcers.
Ehrmann Drugs in the treatment of peptic ulcer and hypersecretion
Gaginella et al. Influence of Antacids on the Gastric Antisecretory Activity of the Synthetic Prostanoid (8R, 11R, 12S, 15R, 5Z, 13E)-15-(Acetyloxy)-11, 16, 16-trimethyl-9-oxoprosta-5, 13-dien-1-oic Acid in Dogs
KR960021033A (en) Pharmaceutical composition containing bamboo salt and antacid
Tallarida et al. Dyazide®(Smith Kline & French) Triamterene: Hydrochlorothiazide
Jang Studies on Eurytrema pancreaticum (V) Experiment for anthelmintic effect

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid